Who Supplies Hydrochlorothiazide to India from BANGLADESH

Importing finished pharmaceutical formulations containing Hydrochlorothiazide into India requires compliance with the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The Central Drugs Standard Control Organization (CDSCO) mandates that both the drug and the manufacturing site be registered. For new drugs, approval under Rule 122E is necessary before registration or import. Applications for registration and import should be submitted to the Drugs Controller General (India) at CDSCO. The registration process involves submitting Form 40 or 41, along with required documents such as the Free Sale Certificate, Certificate of Pharmaceutical Product (CoPP), and stability data. The timeline for import drug registration varies but typically ranges from 6 to 12 months, depending on the completeness of the application and regulatory assessments. Hydrochlorothiazide formulations under HS Code 30049079 are subject to these registration requirements.

Imported finished pharmaceutical formulations containing Hydrochlorothiazide must undergo quality testing at CDSCO-approved laboratories. Batch-wise testing is mandatory, with each batch requiring a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, adhering to ICH Zone IV guidelines, is essential to demonstrate the product's shelf-life under Indian climatic conditions. Port inspection by customs drug inspectors is conducted to verify the authenticity and quality of the imported formulations. These measures ensure that imported Hydrochlorothiazide formulations meet the safety and efficacy standards set by Indian regulatory authorities.

Between 2024 and 2026, the CDSCO has implemented several regulatory updates affecting the import of finished pharmaceutical formulations. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially impacting the volume of finished formulation imports. Bilateral agreements between India and Bangladesh have facilitated smoother trade relations, including mutual recognition of Good Manufacturing Practices (GMP), which may influence import policies and procedures. These developments aim to balance the promotion of domestic industry with the need for imported pharmaceutical products.

India imports finished Hydrochlorothiazide formulations to meet the demand for specific dosage forms and branded products not available domestically. The domestic capacity may not fully satisfy the market needs for certain formulations, leading to reliance on imports. The market size for Hydrochlorothiazide formulations in India is substantial, driven by the prevalence of hypertension and related cardiovascular conditions. Imports play a crucial role in ensuring the availability of a diverse range of Hydrochlorothiazide formulations to cater to the varied preferences and requirements of Indian patients.

The import duty structure for Hydrochlorothiazide formulations under HS Code 30049079 includes a Basic Customs Duty (BCD) of 10%. Additionally, a Social Welfare Surcharge (SWS) of 10% on BCD is applicable. Integrated Goods and Services Tax (IGST) is levied as per prevailing rates, which are subject to change. There are no specific exemptions or concessional duties for Bangladesh-origin Hydrochlorothiazide formulations under this HS Code. The total landed duty percentage combines these components, impacting the final cost of imported formulations.

India sources finished Hydrochlorothiazide formulations from Bangladesh due to competitive advantages such as cost-effectiveness, quality compliance with international standards, and the ability to supply specific dosage forms or branded products not readily available domestically. While other suppliers like China, Germany, and the United States also export Hydrochlorothiazide formulations to India, Bangladesh's proximity, favorable trade relations, and established manufacturing capabilities make it a preferred source. Bangladesh's share in India's Hydrochlorothiazide import market is significant, reflecting its competitive position.

India imports finished Hydrochlorothiazide formulations from Bangladesh due to strategic reasons such as cost-effectiveness, the availability of patented formulations, specialized dosage forms, and technology-licensed products. Bangladesh supplies specific formulations that India does not manufacture domestically, fulfilling market needs and patient preferences. This sourcing strategy ensures a diverse and comprehensive range of Hydrochlorothiazide formulations in the Indian market.

When compared to other origins like China, the European Union, and the United States, Bangladesh offers advantages in terms of competitive pricing, quality compliance with international standards, and the ability to supply specific formulations not readily available from other sources. While other countries may offer similar products, Bangladesh's proximity, favorable trade relations, and established manufacturing capabilities make it a preferred source for Hydrochlorothiazide formulations.

Potential risks for Indian importers sourcing Hydrochlorothiazide formulations from Bangladesh include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have been minimal, but it's prudent for importers to monitor these risks and develop mitigation strategies.

1. 1Dual-Sourcing: Engage multiple suppliers to mitigate risks associated with single-source dependency.
2. 2Inventory Planning: Maintain optimal inventory levels to buffer against potential supply chain disruptions.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP), to manage financial exposure.
4. 4Minimum Order Quantities (MOQs): Clarify MOQs with suppliers to ensure alignment with demand forecasts and inventory strategies.
5. 5Supplier Qualification: Conduct